miR-342

miR-342 is a microRNA-based therapeutic candidate being investigated for its tumor-suppressive properties in multiple myeloma (MM). It functions by directly targeting the 3' untranslated region (UTR) of the Runt-related transcription factor 2 (Runx2) mRNA, leading to its downregulation. Runx2 is a transcription factor that is typically overexpressed in MM and serves as a major driver of tumor progression and bone dissemination. By suppressing Runx2, miR-342 subsequently inhibits downstream signaling pathways, including Akt, β-catenin, and survivin, and reduces the expression of metastasis-promoting genes such as RANKL, DKK1, and DMP1. Preclinical research conducted at the University of Alabama at Birmingham has demonstrated that reconstituting MM cells with synthetic miR-342 mimics reduces tumor cell viability, migration, and in vivo growth in mouse models.

Other names

microRNA-342microRNA342microRNA 342hsa-miR-342hsa-miR342hsa-miR 342hsa-miR-342-3phsa-miR342-3phsa-miR 342-3phsa-miR-342-5phsa-miR342-5phsa-miR 342-5p